Lv5
880 积分 2023-08-01 加入
Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
8天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
2个月前
已完结
Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis
3个月前
已完结
Cardiac toxicity of HER-2 targeting antibody–drug conjugates: overview and clinical implications
3个月前
已完结
Novel antibody-drug conjugates based on DXd-ADC technology
4个月前
已完结
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
4个月前
已完结
crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
4个月前
已完结
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer
4个月前
已完结
Resistance Mechanisms and Post-Trastuzumab Deruxtecan (T-DXd) Strategies in HER2+ and HER2-Low Breast Cancer: From Biology to Clinical Practice
4个月前
已完结
Resistance Mechanisms and Post-Trastuzumab Deruxtecan (T-DXd) Strategies in HER2+ and HER2-Low Breast Cancer: From Biology to Clinical Practice
4个月前
已关闭
皖公网安备34019202002308
